Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development

Current Opinion in Biotechnology

Volumn 18, Issue 6, 2007, Pages 529-536

  Rimmelzwaan, Guus F ^a   Fouchier, Ron AM ^a   Osterhaus, Albert DME ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIRDS; VACCINES; VIRUSES;

LYMPHOCYTES; VACCINE DEVELOPMENT;

CYTOTOXICITY;

ADENOVIRUS VECTOR; CHOLESTEROL; DNA VACCINE; GAG PROTEIN; GLYCOSIDE; HERPESVIRUS VECTOR; INFLUENZA VACCINE; ISCOM; LIVE VACCINE; NEF PROTEIN; PHOSPHOLIPID; POL PROTEIN; QUIL A; VIROSOME; VIRUS PROTEIN; VIRUS VECTOR;

CYTOTOXIC T LYMPHOCYTE; DRUG RESEARCH; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; REVIEW; VIRUS IMMUNITY;

ANIMALS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE; T-LYMPHOCYTES, CYTOTOXIC;

AVES; INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 37549015223     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2007.11.002     Document Type: Review

References (89)

1. Cassetti M.C., Couch R., Wood J., and Pervikov Y. Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, February 26-27, 2004. Vaccine 23 (2005) 1529-1533
2. Cassetti M.C., Katz J.M., and Wood J. Report of a consultation on role of immunological assays to evaluate efficacy of influenza vaccines. Initiative for Vaccine Research and Global Influenza Programme, World Health Organization, Geneva, Switzerland, January 25, 2005. Vaccine 24 (2006) 541-543
3. de Jong J.C., Palache A.M., Beyer W.E., Rimmelzwaan G.F., Boon A.C., and Osterhaus A.D. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115 (2003) 63-73
4. Jung S., Unutmaz D., Wong P., Sano G., De los Santos K., Sparwasser T., Wu S., Vuthoori S., Ko K., Zavala F., et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 17 (2002) 211-220
5. Zammit D.J., Cauley L.S., Pham Q.M., and Lefrancois L. Dendritic cells maximize the memory CD8 T cell response to infection. Immunity 22 (2005) 561-570
6. Schulman J.L., and Kilbourne E.D. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J Bacteriol 89 (1965) 170-174
7. Zweerink H.J., Courtneidge S.A., Skehel J.J., Crumpton M.J., and Askonas B.A. Cytotoxic T cells kill influenza virus infected cells but do not distinguish between serologically distinct type A viruses. Nature 267 (1977) 354-356
8. Askonas B.A., Taylor P.M., and Esquivel F. Cytotoxic T cells in influenza infection. Ann N Y Acad Sci 532 (1988) 230-237
9. Kees U., and Krammer P.H. Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants. J Exp Med 159 (1984) 365-377
10. McMichael A.J., Gotch F.M., Noble G.R., and Beare P.A. Cytotoxic T-cell immunity to influenza. N Engl J Med 309 (1983) 13-17. This study is still unique and demonstrates in humans that in the absence of specific antibodies the presence of CTL activity correlates with reduced viral shedding.
11. McMichael A.J., Michie C.A., Gotch F.M., Smith G.L., and Moss B. Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 67 Pt 4 (1986) 719-726
12. Townsend A.R., and Skehel J.J. The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J Exp Med 160 (1984) 552-563
13. Gotch F., McMichael A., Smith G., and Moss B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med 165 (1987) 408-416
14. Yewdell J.W., Bennink J.R., Smith G.L., and Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 82 (1985) 1785-1789
15. Yap K.L., Ada G.L., and McKenzie I.F. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 273 (1978) 238-239
16. Yap K.L., and Ada G.L. The recovery of mice from influenza virus infection: adoptive transfer of immunity with immune T lymphocytes. Scand J Immunol 7 (1978) 389-397
17. Wells M.A., Ennis F.A., and Albrecht P. Recovery from a viral respiratory infection. II. Passive transfer of immune spleen cells to mice with influenza pneumonia. J Immunol 126 (1981) 1042-1046
18. Lukacher A.E., Braciale V.L., and Braciale T.J. In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med 160 (1984) 814-826
19. Taylor P.M., and Askonas B.A. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 58 (1986) 417-420
20. Liang S., Mozdzanowska K., Palladino G., and Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 152 (1994) 1653-1661
21. Seo S.H., Peiris M., and Webster R.G. Protective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/96-like H5N1 influenza virus is correlated with the proportion of pulmonary CD8(+) T cells expressing gamma interferon. J Virol 76 (2002) 4886-4890
22. Seo S.H., and Webster R.G. Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J Virol 75 (2001) 2516-2525
23. Kreijtz J.H., Bodewes R., van Amerongen G., Kuiken T., Fouchier R.A., Osterhaus A.D., and Rimmelzwaan G.F. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25 (2007) 612-620
24. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 (1993) 1745-1749. This study nicely demonstrates that the induction of cell mediated immunity specific for the conserved nucleoprotein by DNA vaccination confers protection against various subtypes of influenza virus in the mouse model.
25. Ulmer J.B., Fu T.M., Deck R.R., Friedman A., Guan L., DeWitt C., Liu X., Wang S., Liu M.A., Donnelly J.J., et al. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 72 (1998) 5648-5653
26. Ulmer J.B., Deck R.R., Dewitt C.M., Donnhly J.I., and Liu M.A. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 89 (1996) 59-67
27. Donnelly J.J., Friedman A., Ulmer J.B., and Liu M.A. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 15 (1997) 865-868
28. Wraith D.C., Vessey A.E., and Askonas B.A. Purified influenza virus nucleoprotein protects mice from lethal infection. J Gen Virol 68 Pt 2 (1987) 433-440
29. Tite J.P., Gao X.M., Hughes-Jenkins C.M., Lipscombe M., O'Callaghan D., Dougan G., and Liew F.Y. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. III. Delivery of recombinant nucleoprotein to the immune system using attenuated Salmonella typhimurium as a live carrier. Immunology 70 (1990) 540-546
30. Tite J.P., Hughes-Jenkins C., O'Callaghan D., Dougan G., Russell S.M., Gao X.M., and Liew F.Y. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection. Immunology 71 (1990) 202-207
31. Tite J.P., Russell S.M., Dougan G., O'Callaghan D., Jones I., Brownlee G., and Liew F.Y. Antiviral immunity induced by recombinant nucleoprotein of influenza A virus. I. Characteristics and cross-reactivity of T cell responses. J Immunol 141 (1988) 3980-3987
32. Rimmelzwaan G.F., and Osterhaus A.D. Cytotoxic T lymphocyte memory: role in cross-protective immunity against influenza?. Vaccine 13 (1995) 703-705
33. Epstein S.L. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193 (2006) 49-53. Very interesting paper that suggests that prior exposure to influenza viruses of the H1N1 subtype induced heterosubtypic immunity against influenza viruses of the H2N2 subtype during the 1957 pandemic.
34. Jameson J., Cruz J., Terajima M., and Ennis F.A. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 162 (1999) 7578-7583
35. Smallman-Raynor M., and Cliff A.D. Avian influenza A (H5N1) age distribution in humans. Emerg Infect Dis 13 (2007) 510-512. Clear documentation of the disproportionate age distribution of H5N1 cases.
36. Berkhoff E.G., Geelhoed-Mieras M.M., Fouchier R.A., Osterhaus A.D., and Rimmelzwaan G.F. Assessment of the extent of variation in influenza A virus cytotoxic T-lymphocyte epitopes by using virus-specific CD8+ T-cell clones. J Gen Virol 88 (2007) 530-535
37. Voeten J.T., Bestebroer T.M., Nieuwkoop N.J., Fouchier R.A., Osterhaus A.D., and Rimmelzwaan G.F. Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol 74 (2000) 6800-6807. First demonstration that influenza viruses can accumulate mutations in CTL epitopes associated with escape from recognition by specific CTL.
38. Boon A.C., de Mutsert G., Graus Y.M., Fouchier R.A., Sintnicolaas K., Osterhaus A.D., and Rimmelzwaan G.F. Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. J Virol 76 (2002) 2567-2572
39. Rimmelzwaan G.F., Boon A.C., Voeten J.T., Berkhoff E.G., Fouchier R.A., and Osterhaus A.D. Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. Virus Res 103 (2004) 97-100
40. Boon A.C., de Mutsert G., van Baarle D., Smith D.J., Lapedes A.S., Fouchier R.A., Sintnicolaas K., Osterhaus A.D., and Rimmelzwaan G.F. Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J Immunol 172 (2004) 2453-2460
41. Berkhoff E.G., Boon A.C., Nieuwkoop N.J., Fouchier R.A., Sintnicolaas K., Osterhaus A.D., and Rimmelzwaan G.F. A mutation in the HLA-B*2705-restricted NP383-391 epitope affects the human influenza A virus-specific cytotoxic T-lymphocyte response in vitro. J Virol 78 (2004) 5216-5222
42. Berkhoff E.G., Geelhoed-Mieras M.M., Verschuren E.J., van Baalen C.A., Gruters R.A., Fouchier R.A., Osterhaus A.D., and Rimmelzwaan G.F. The loss of immunodominant epitopes affects interferon-gamma production and lytic activity of the human influenza virus-specific cytotoxic T lymphocyte response in vitro. Clin Exp Immunol 148 (2007) 296-306
43. Rimmelzwaan G.F., Berkhoff E.G., Nieuwkoop N.J., Fouchier R.A., and Osterhaus A.D. Functional compensation of a detrimental amino acid substitution in a cytotoxic-T-lymphocyte epitope of influenza a viruses by comutations. J Virol 78 (2004) 8946-8949
44. Rimmelzwaan G.F., Berkhoff E.G., Nieuwkoop N.J., Smith D.J., Fouchier R.A., and Osterhaus A.D. Full restoration of viral fitness by multiple compensatory co-mutations in the nucleoprotein of influenza A virus cytotoxic T-lymphocyte escape mutants. J Gen Virol 86 (2005) 1801-1805
45. Gog J.R., Rimmelzwaan G.F., Osterhaus A.D., and Grenfell B.T. Population dynamics of rapid fixation in cytotoxic T lymphocyte escape mutants of influenza A. Proc Natl Acad Sci U S A 100 (2003) 11143-11147
46. Berkhoff E.G., de Wit E., Geelhoed-Mieras M.M., Boon A.C., Symons J., Fouchier R.A., Osterhaus A.D., and Rimmelzwaan G.F. Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes. J Virol 79 (2005) 11239-11246. This study provides evidence that certain epitopes are under functional constraints, which may explain the conserved nature of some of these epitopes.
47. Berkhoff E.G., de Wit E., Geelhoed-Mieras M.M., Boon A.C., Symons J., Fouchier R.A., Osterhaus A.D., and Rimmelzwaan G.F. Fitness costs limit escape from cytotoxic T lymphocytes by influenza A viruses. Vaccine 24 (2006) 6594-6596
48. Yewdell J.W., and Bennink J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17 (1999) 51-88
49. Yewdell J.W., and Del Val M. Immunodominance in TCD8+ responses to viruses: cell biology, cellular immunology, and mathematical models. Immunity 21 (2004) 149-153
50. Yewdell J.W. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25 (2006) 533-543
51. Chen W., Pang K., Masterman K.A., Kennedy G., Basta S., Dimopoulos N., Hornung F., Smyth M., Bennink J.R., and Yewdell J.W. Reversal in the immunodominance hierarchy in secondary CD8+ T cell responses to influenza A virus: roles for cross-presentation and lysis-independent immunodomination. J Immunol 173 (2004) 5021-5027
52. Boon A.C., de Mutsert G., Graus Y.M., Fouchier R.A., Sintnicolaas K., Osterhaus A.D., and Rimmelzwaan G.F. The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype. J Virol 76 (2002) 582-590
53. Belz G.T., Xie W., Altman J.D., and Doherty P.C. A previously unrecognized H-2D(b)-restricted peptide prominent in the primary influenza A virus-specific CD8(+) T-cell response is much less apparent following secondary challenge. J Virol 74 (2000) 3486-3493
54. Belz G.T., Stevenson P.G., and Doherty P.C. Contemporary analysis of MHC-related immunodominance hierarchies in the CD8+ T cell response to influenza A viruses. J Immunol 165 (2000) 2404-2409
55. Boon A.C., De Mutsert G., Fouchier R.A., Sintnicolaas K., Osterhaus A.D., and Rimmelzwaan G.F. Preferential HLA usage in the influenza virus-specific CTL response. J Immunol 172 (2004) 4435-4443
56. Tussey L.G., Rowland-Jones S., Zheng T.S., Androlewicz M.J., Cresswell P., Frelinger J.A., and McMichael A.J. Different MHC class I alleles compete for presentation of overlapping viral epitopes. Immunity 3 (1995) 65-77
57. Cho Y., Basta S., Chen W., Bennink J.R., and Yewdell J.W. Heat-aggregated noninfectious influenza virus induces a more balanced CD8(+)-T-lymphocyte immunodominance hierarchy than infectious virus. J Virol 77 (2003) 4679-4684
58. Gorse G.J., and Belshe R.B. Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults. J Clin Microbiol 28 (1990) 2539-2550
59. Gorse G.J., and Belshe R.B. Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses. Scand J Infect Dis 23 (1991) 7-17
60. Gorse G.J., Campbell M.J., Otto E.E., Powers D.C., Chambers G.W., and Newman F.K. Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. J Infect Dis 172 (1995) 1-10
61. Keitel W.A., and Piedra P.A. Live cold-adapted, reassortant influenza vaccines (USA). In: Nicholson K.G., Webster R.G., and Hay A.J. (Eds). Textbook of Influenza (1998), Blackwell Science 373-390
62. Beyer W.E., Palache A.M., de Jong J.C., and Osterhaus A.D. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20 (2002) 1340-1353
63. Dudek T., and Knipe D.M. Replication-defective viruses as vaccines and vaccine vectors. Virology 344 (2006) 230-239
64. Liniger M., Zuniga A., and Naim H.Y. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 6 (2007) 255-266
65. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., Tang A., Chen M., Huang L., Harris V., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77 (2003) 6305-6313
66. Dubey S., Clair J., Fu T.M., Guan L., Long R., Mogg R., Anderson K., Collins K.B., Gaunt C., Fernandez V.R., et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 45 (2007) 20-27
67. Anonymous: HIV vaccine failure prompts Merck to halt trial. Nature 2007, 449:390.
68. Morein B., Sundquist B., Hoglund S., Dalsgaard K., and Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308 (1984) 457-460
69. Rimmelzwaan G.F., and Osterhaus A.D.M.E. ISCOMs: materials, preparation, antigen delivery and immune response. In: Gander B., Merkle H.P., and Corradin G. (Eds). Antigen Delivery Systems (1997), Harwood Academic Publishers 123-138
70. Rimmelzwaan G.F., Baars M., van Beek R., van Amerongen G., Lovgren-Bengtsson K., Claas E.C., and Osterhaus A.D. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol 78 Pt 4 (1997) 757-765
71. Rimmelzwaan G.F., Claas E.C., van Amerongen G., de Jong J.C., and Osterhaus A.D. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 17 (1999) 1355-1358
72. van Binnendijk R.S., van Baalen C.A., Poelen M.C., de Vries P., Boes J., Cerundolo V., Osterhaus A.D., and UytdeHaag F.G. Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition. J Exp Med 176 (1992) 119-128
73. Voeten J.T., Rimmelzwaan G.F., Nieuwkoop N.J., Lovgren-Bengtsson K., and Osterhaus A.D. Introduction of the haemagglutinin transmembrane region in the influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8(+) cytotoxic T lymphocytes. Vaccine 19 (2000) 514-522
74. Rimmelzwaan G.F., Nieuwkoop N., Brandenburg A., Sutter G., Beyer W.E., Maher D., Bates J., and Osterhaus A.D. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 19 (2000) 1180-1187
75. Ennis F.A., Cruz J., Jameson J., Klein M., Burt D., and Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 259 (1999) 256-261
76. Sambhara S., Woods S., Arpino R., Kurichh A., Tamane A., Underdown B., Klein M., Lovgren Bengtsson K., Morein B., and Burt D. Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes. J Infect Dis 177 (1998) 1266-1274
77. Sambhara S., Kurichh A., Miranda R., Tumpey T., Rowe T., Renshaw M., Arpino R., Tamane A., Kandil A., James O., et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 211 (2001) 143-153
78. Gluck R., Mischler R., Finkel B., Que J.U., Scarpa B., and Cryz Jr. S.J. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344 (1994) 160-163
79. Gluck R., Burri K.G., and Metcalfe I. Adjuvant and antigen delivery properties of virosomes. Curr Drug Deliv 2 (2005) 395-400
80. Daemen T., de Mare A., Bungener L., de Jonge J., Huckriede A., and Wilschut J. Virosomes for antigen and DNA delivery. Adv Drug Deliv Rev 57 (2005) 451-463
81. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., and Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science 247 (1990) 1465-1468
82. Robinson H.L., Hunt L.A., and Webster R.G. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 11 (1993) 957-960
83. Donnelly J.J., Friedman A., Martinez D., Montgomery D.L., Shiver J.W., Motzel S.L., Ulmer J.B., and Liu M.A. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1 (1995) 583-587
84. Epstein S.L., Stack A., Misplon J.A., Lo C.Y., Mostowski H., Bennink J., and Subbarao K. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge. Int Immunol 12 (2000) 91-101
85. Fu T.M., Guan L., Friedman A., Schofield T.L., Ulmer J.B., Liu M.A., and Donnelly J.J. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J Immunol 162 (1999) 4163-4170
86. Ljungberg K., Wahren B., Almqvist J., Hinkula J., Linde A., and Winberg G. Effective construction of DNA vaccines against variable influenza genes by homologous recombination. Virology 268 (2000) 244-250
87. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., and Nabel G.J. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23 (2005) 5404-5410
88. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol 18 (2000) 927-974. Excellent review on the topic.
89. Klinman D.M., Takeno M., Ichino M., Gu M., Yamshchikov G., Mor G., and Conover J. DNA vaccines: safety and efficacy issues. Springer Semin Immunopathol 19 (1997) 245-256